Patients New Evidation CEO to double down on patient data empowerment pharmaphorum spoke with Leslie Olay Wilberforce, Evidation's new CEO, about the company's unique approach to real-world data and her future plans.
News Taiho's late-stage Duchenne candidate fails trial Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
News Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.
News Apogee rises as long-acting eczema drug heads for phase 3 Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.
News Pharma welcomes EU push to restore life sciences sector European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward."
News Novartis drug flunks phase 3 test in giant cell arteritis Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.